PPIG and infection: Here, we showed that inhibition of Cyp activity by CsA, a licensed drug with well-known pharmacokinetics and safety profiles67,68, and its non-immunosuppressive derivative NIM81142 led to significantly decreased leukocytosis upon infection with PT-producing B. pertussis strains.